Fortis Healthcare CFO Gagandeep Singh Bedi quits

NEW DELHI: Fortis Healthcare on Thursday said its Chief Financial Officer Gagandeep Singh Bedi has resigned citing personal reasons.

The Board of Directors of the company at its meeting held today have considered Bedi’s resignation from the services of the company, and accepted the same, with effect from September 30, 2018, Fortis Healthcare said in a filing to BSE.

The resignation is due to personal reasons, it added.

Shares of Fortis Healthcare today closed at Rs 148.70 per scrip on BSE, down 0.07 per cent from the previous close.

  • Related Posts

    ‘Made in India’ Surgical Robot SSiMantra makes Powerful Presence felt in UK

    NHS fame Indian Surgeon’s Audacity of comparing SSiMantra with World’s Best was received Well UK/ India: That SSiMantra, the only ‘Made in India’, best in class surgical robot, is now…

    Physicians Forum of India all set to bat a 1000 in CME for Healthy India

    PHYFiCON 2026 being organized for Milestone Celebration of Knowledge, Learning & Excellence on August 23 New Delhi: The mission was to equip doctors with updated medical knowledge for healthy India.…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Dr Reddy’s delays semaglutide supplies due to API issue

    Dr Reddy’s delays semaglutide supplies due to API issue

    India Tightens Rules On Alcohol-Containing Medicines

    India Tightens Rules On Alcohol-Containing Medicines

    One more held in spurious plasma racket; police say he supplied 12 boxes

    One more held in spurious plasma racket; police say he supplied 12 boxes

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Drug regulator orders fresh safety labels for five common antimicrobials

    Drug regulator orders fresh safety labels for five common antimicrobials

    Rajasthan recalls labour-inducing drug after quality test failure

    Rajasthan recalls labour-inducing drug after quality test failure